BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36736685)

  • 21. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
    Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
    Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case.
    Kientz C; Prieur F; Clemenson A; Joly MO; Stachowicz ML; Auclair J; Attignon V; Schiappa R; Wang Q
    Fam Cancer; 2020 Jan; 19(1):11-14. PubMed ID: 31745674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutation in sporadic colorectal cancer and Lynch syndrome.
    Thiel A; Heinonen M; Kantonen J; Gylling A; Lahtinen L; Korhonen M; Kytölä S; Mecklin JP; Orpana A; Peltomäki P; Ristimäki A
    Virchows Arch; 2013 Nov; 463(5):613-21. PubMed ID: 23963522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset nonfamilial nonpolyposis colorectal cancer.
    Antelo M; Golubicki M; Roca E; Mendez G; Carballido M; Iseas S; Cuatrecasas M; Moreira L; Sanchez A; Carballal S; Castells A; Boland CR; Goel A; Balaguer F
    Int J Cancer; 2019 Aug; 145(3):705-713. PubMed ID: 30693488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
    Haraldsdottir S; Hampel H; Wu C; Weng DY; Shields PG; Frankel WL; Pan X; de la Chapelle A; Goldberg RM; Bekaii-Saab T
    Genet Med; 2016 Sep; 18(9):863-8. PubMed ID: 26866578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
    Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
    Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer.
    Xiao B; Luo J; Xie E; Kong L; Tang J; Liu D; Mao L; Sui Q; Li W; Hong Z; Pan Z; Jiang W; Ding PR
    Eur J Hum Genet; 2020 Nov; 28(11):1555-1562. PubMed ID: 32661327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
    Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
    Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
    Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
    Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.
    Gausachs M; Mur P; Corral J; Pineda M; González S; Benito L; Menéndez M; Espinàs JA; Brunet J; Iniesta MD; Gruber SB; Lázaro C; Blanco I; Capellá G
    Eur J Hum Genet; 2012 Jul; 20(7):762-8. PubMed ID: 22274583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating Tumor Sequencing Into Clinical Practice for Patients With Mismatch Repair-Deficient Lynch Syndrome Spectrum Cancers.
    Dixon K; Asrat MJ; Bedard AC; Binnington K; Compton K; Cremin C; Heidary N; Lohn Z; Lovick N; McCullum M; Mindlin A; O'Loughlin M; Petersen T; Portigal-Todd C; Scott J; St-Martin G; Thompson J; Turnbull R; Mung SW; Hong Q; Bezeau M; Bosdet I; Tucker T; Young S; Yip S; Aubertin G; Blood KA; Nuk J; Sun S; Schrader KA
    Clin Transl Gastroenterol; 2021 Aug; 12(8):e00397. PubMed ID: 34397043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N_LyST: a simple and rapid screening test for Lynch syndrome.
    Susanti S; Fadhil W; Ebili HO; Asiri A; Nestarenkaite A; Hadjimichael E; Ham-Karim HA; Field J; Stafford K; Matharoo-Ball B; Hassall JC; Sharif A; Oniscu A; Ilyas M
    J Clin Pathol; 2018 Aug; 71(8):713-720. PubMed ID: 29472252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy.
    Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D
    Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?
    Lobo J; Pinto C; Freitas M; Pinheiro M; Vizcaino R; Oliva E; Teixeira MR; Jerónimo C; Bartosch C
    Virchows Arch; 2017 Mar; 470(3):347-352. PubMed ID: 27915441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
    Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.
    Mueller J; Gazzoli I; Bandipalliam P; Garber JE; Syngal S; Kolodner RD
    Cancer Res; 2009 Sep; 69(17):7053-61. PubMed ID: 19690142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.